Caffeic Acid Phenethyl Ester as a Potential Treatment for Advanced Prostate Cancer Targeting Akt Signaling

International Journal of Molecular Sciences

Hui-Ping Lin⁴  Ching-Yu Lin⁴  Chun-Chieh Liu³  Liang-Cheng Su⁴  Chieh Huo⁴  Ying-Yu Kuo⁴  Jen-Chih Tseng⁴  Jong-Ming Hsu¹  Chi-Kuan Chen² 

[1] Department of Urology, Mackay Memorial Hospital, Taipei City 10449, Taiwan; E-Mail:;Department of Pathology, Mackay Memorial Hospital, Taipei City 10449, Taiwan; E-Mail:;Division of Cardiology, Department of Internal Medicine, Mackay Memorial Hospital, Taipei City 10449, Taiwan; E-Mail:;Institute of Cellular and System Medicine, National Health Research Institutes, Miaoli 35053, Taiwan; E-Mails:

关键词: prostate cancer;    caffeic acid phenethyl ester;    Akt;    LNCaP;    PC-3;   

DOI  :  10.3390/ijms14035264

来源: mdpi

【 摘 要 】

Prostate cancer is the fifth most common cancer overall in the world. Androgen ablation therapy is the primary treatment for metastatic prostate cancer. However, most prostate cancer patients receiving the androgen ablation therapy ultimately develop recurrent castration-resistant tumors within 1–3 years after treatment. The median overall survival time is 1–2 years after tumor relapse. Chemotherapy shows little effect on prolonging survival for patients with metastatic hormone-refractory prostate cancer. More than 80% of prostate tumors acquire mutation or deletion of tumor suppressor phosphatase and tensin homolog (PTEN), a negative regulator of PI3K/Akt signaling, indicating that inhibition of PI3K/Akt might be a potential therapy for advanced prostate tumors. Caffeic acid phenethyl ester (CAPE) is a strong antioxidant extracted from honeybee hive propolis. CAPE is a well-known NF-κB inhibitor. CAPE has been used in folk medicine as a potent anti-inflammatory agent. Recent studies indicate that CAPE treatment suppresses tumor growth and Akt signaling in human prostate cancer cells. We discuss the potential of using CAPE as a treatment for patients with advanced prostate cancer targeting Akt signaling pathway in this review article.

【 授权许可】

CC BY   
© 2013 by the authors; licensee MDPI, Basel, Switzerland.